Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23796108 | 1.00 | MAP4K4 (0.49) | MAP4K4CYP2C8APPALOX5APFEN1 | |
| SCHEMBL30290029 | 0.83 | NPSR1 (0.44) | MAP4K4ALOX5APFEN1AKR1C3AKR1C2 | |
| SCHEMBL23796136 | 0.83 | NPSR1 (0.44) | MAP4K4ALOX5APFEN1AKR1C3AKR1C2 | |
| SCHEMBL23796208 | 0.82 | SCN9A (0.51) | MAP4K4 | |
| SCHEMBL30290061 | 0.82 | SCN9A (0.51) | MAP4K4 | |
| SCHEMBL23795940 | 0.82 | MAP4K4 (0.48) | MAP4K4CYP2C8P2RY14SLC6A2PTPN11 | |
| SCHEMBL30289940 | 0.82 | MAP4K4 (0.48) | MAP4K4CYP2C8P2RY14SLC6A2PTPN11 | |
| SCHEMBL22559137 | 0.80 | IGFBP3 (0.43) | MAP4K4PTPN11SRD5A2 | |
| SCHEMBL30867628 | 0.80 | IGFBP3 (0.43) | MAP4K4PTPN11SRD5A2 | |
| SCHEMBL23796234 | 0.75 | PSMD14 (0.52) | MAP4K4CYP2C8P2RY14SLC6A2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | MAP4K4 1283/4885CYP2C8 2749/4885APP 3882/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | MAP4K4 1283/4885CYP2C8 2749/4885APP 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.